333 related articles for article (PubMed ID: 36650542)
1. FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma.
Chianese U; Papulino C; Ali A; Ciardiello F; Cappabianca S; Altucci L; Carafa V; Benedetti R
J Transl Med; 2023 Jan; 21(1):32. PubMed ID: 36650542
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer.
Bian Y; Yu Y; Wang S; Li L
Biochem Biophys Res Commun; 2015 Aug; 463(4):612-7. PubMed ID: 26043686
[TBL] [Abstract][Full Text] [Related]
3. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth.
Gang X; Yang Y; Zhong J; Jiang K; Pan Y; Karnes RJ; Zhang J; Xu W; Wang G; Huang H
Oncotarget; 2016 Mar; 7(12):15135-49. PubMed ID: 26934656
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.
Migita T; Ruiz S; Fornari A; Fiorentino M; Priolo C; Zadra G; Inazuka F; Grisanzio C; Palescandolo E; Shin E; Fiore C; Xie W; Kung AL; Febbo PG; Subramanian A; Mucci L; Ma J; Signoretti S; Stampfer M; Hahn WC; Finn S; Loda M
J Natl Cancer Inst; 2009 Apr; 101(7):519-32. PubMed ID: 19318631
[TBL] [Abstract][Full Text] [Related]
5. FABP5 regulates lipid metabolism to facilitate pancreatic neuroendocrine neoplasms progression via FASN mediated Wnt/β-catenin pathway.
Lu F; Ye M; Hu C; Chen J; Yan L; Gu D; Xu L; Tian Y; Bai J; Tang Q
Cancer Sci; 2023 Sep; 114(9):3553-3567. PubMed ID: 37302809
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer.
Karantanos T; Karanika S; Wang J; Yang G; Dobashi M; Park S; Ren C; Li L; Basourakos SP; Hoang A; Efstathiou E; Wang X; Troncoso P; Titus M; Broom B; Kim J; Corn PG; Logothetis CJ; Thompson TC
Oncotarget; 2016 Jul; 7(29):46321-46334. PubMed ID: 27331874
[TBL] [Abstract][Full Text] [Related]
7. FASN Protein Overexpression Indicates Poor Biochemical Recurrence-Free Survival in Prostate Cancer.
Cao Z; Xu Y; Guo F; Chen X; Ji J; Xu H; He J; Yu Y; Sun Y; Lu X; Wang F
Dis Markers; 2020; 2020():3904947. PubMed ID: 32655718
[TBL] [Abstract][Full Text] [Related]
8. Downregulated expression of IL‑28RA is involved in the pathogenesis of pancreatic ductal adenocarcinoma.
Liu L; Qi Y; Huang D; Xu Y; Li M; Hong Z; Gu Y; Jia B; Luo X; Zhang S; Zhang S
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195850
[TBL] [Abstract][Full Text] [Related]
9. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
[TBL] [Abstract][Full Text] [Related]
10. An increased expression of long non-coding RNA PANDAR promotes cell proliferation and inhibits cell apoptosis in pancreatic ductal adenocarcinoma.
Jiang Y; Feng E; Sun L; Jin W; You Y; Yao Y; Xu Y
Biomed Pharmacother; 2017 Nov; 95():685-691. PubMed ID: 28886528
[TBL] [Abstract][Full Text] [Related]
11. FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-genomic Features of Prostate Cancer.
Dairo O; DePaula Oliveira L; Schaffer E; Vidotto T; Mendes AA; Lu J; Huynh SV; Hicks J; Sowalsky AG; De Marzo AM; Joshu CE; Hanratty B; Sfanos KS; Isaacs WB; Haffner MC; Lotan TL
Cancer Res Commun; 2024 Jan; 4(1):152-163. PubMed ID: 38112617
[TBL] [Abstract][Full Text] [Related]
12. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
13. SQLE inhibition suppresses the development of pancreatic ductal adenocarcinoma and enhances its sensitivity to chemotherapeutic agents in vitro.
Zhao F; Huang Y; Zhang Y; Li X; Chen K; Long Y; Li F; Ma X
Mol Biol Rep; 2022 Jul; 49(7):6613-6621. PubMed ID: 35552960
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA‑766 inhibits the malignant biological behaviours of pancreatic ductal adenocarcinoma by directly targeting ETS1.
Li S; Yan G; Yue M; Kang Z; Wang L
Mol Med Rep; 2019 Feb; 19(2):1380-1387. PubMed ID: 30569091
[TBL] [Abstract][Full Text] [Related]
15. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
16. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
17. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
[TBL] [Abstract][Full Text] [Related]
18. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C
Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369
[TBL] [Abstract][Full Text] [Related]
19. Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma.
Fu XL; Liu DJ; Yan TT; Yang JY; Yang MW; Li J; Huo YM; Liu W; Zhang JF; Hong J; Hua R; Chen HY; Sun YW
Sci Rep; 2016 Sep; 6():33535. PubMed ID: 27628540
[TBL] [Abstract][Full Text] [Related]
20. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma.
Zhao X; Liu Y; Li Z; Zheng S; Wang Z; Li W; Bi Z; Li L; Jiang Y; Luo Y; Lin Q; Fu Z; Rufu C
J Cell Mol Med; 2018 Jan; 22(1):655-667. PubMed ID: 28984028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
